SFX by Ex Libris Inc.

Title:	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Source:	Science [0036-8075] Vacchelli, Erika yr:2015

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Zitvogel, L. "Immunological aspects of cancer chemotherapy." Nature reviews. Immunology 8.1 (2007): 59-73.
description	2.	Xu, D. "Comparison of the role of HHIP SNPs in susceptibility to chronic obstructive pulmonary disease between Chinese Han and Mongolian populations." Gene (2017): 50-56.
description	3.	Zheng, D. "Highly Integrated Nano-Platform for Breaking the Barrier between Chemotherapy and Immunotherapy." Nano letters 16.7 (2016): 4341-4347.
description	4.	Chang, Seon H. "T helper 17 cells play a critical pathogenic role in lung cancer." Proceedings of the National Academy of Sciences of the United States of America 111.15 (2014): 5664-5669.
description	5.	Rasmussen, L. "Chemotherapy-induced immunosuppression." Environmental health perspectives 43 (1982): 21-25.
description	6.	Tesniere, A., A. "Molecular characteristics of immunogenic cancer cell death." Cell death and differentiation 15.1 (2008): 3-12.
description	7.	Vacchelli, G. "Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer." Oncoimmunology 5.6 (2016).
description	8.	Fontana, F. "Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?" Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 9.1 (2016): 1-26.
description	9.	Mendes, Tania Filipa S. ha D. "Triple Negative Breast Cancer: Nanosolutions for a Big Challenge." Advanced Science 2.11 (2015): 1500053-.
description	10.	Liang, C. "Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy." Chemical Society reviews 45.22 (2016): 6250-6269.
description	11.	Bernabeu, E. "Novel Soluplus®—TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines." Colloids and surfaces. B, Biointerfaces 140 (2016): 403-411.
description	12.	Occhipinti, S. "Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance In Cancer Patients." Clinical cancer research 20.11 (2014): 2910-21.
description	13.	Chalmin, F. "Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression." Immunity 36.3 (2012): 362-373.
description	14.	Zhong, B. "Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25." Nature Immunology 13.11 (2012): 1110-1117.
description	15.	Chang, Seon H. "Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression." Journal of biological chemistry 285.50 (2010): 38751-38755.
description	16.	Corrie, Pippa G. "Cytotoxic chemotherapy: clinical aspects." Medicine 36.1 (2008): 24-28.
description	17.	Eyerich, S. "Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling." Journal of Clinical Investigation 119.12 (2009): 3573-3585.
description	18.	Steele, TA A. "Chemotherapy-induced immunosuppression and reconstitution of immune function." Leukemia Research 26.4 (2002): 411-414.
description	19.	Tacken, Paul J J. "Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting." Nature reviews. Immunology 7.10 (2007): 790-802.
description	20.	O'Neill, Luke A J F. "Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis." British journal of haematology 139.2 (2007): 185-93.